Schedule 13G ownership disclosure
CRISPR Therapeutics AG
Security class unavailable · CUSIP: H17182108
Event date: 2022-12-30
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 5,560,492
- Percent of class
- 7.1000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001562230-23-000029
- Form type
- SC 13G
- Filer
- CRISPR Therapeutics AG
- CIK
- CIK 1674416
- Filed
- Feb 13, 2023
- Reporting period
- Dec 30, 2022
- Description
- Schedule 13G beneficial ownership